Tumours develop through the accumulation of mutations in DNA. Recent advances in high-throughput (next-generation) DNA sequencing allow researchers rapid identification of mutations in a genome. This has increased understanding of the biology of cancer cells, and has led to more effective drugs and better predictions of patient outcomes. However, maximizing the clinical use of next-generation sequencing data requires sophisticated software to improve the analysis of genomes and identification of mutant sequences related to tumours.
Drs. Sohrab Shah and Paul C. Boutros are developing innovative software that will improve patient care by identifying and analyzing the mutations involved in cancer progression.